Antifungal Effects and Potential Mechanisms of Benserazide Hydrochloride Alone and in Combination with Fluconazole Against Candida albicans

References

• ZavrelM, WhiteTC. Medically important fungi respond to azole drugs: an update. Future Microbiol. 2015;10(8):1355–1373. doi:10.2217/FMB.15.4726234644
   PubMed Web of Science ®Google Scholar
• TingSY, IsholaOA, AhmedMA, et al. Metabolic adaptation via regulated enzyme degradation in the pathogenic yeast Candida albicans. J Mycol Med. 2017;27(1):98–108. doi:10.1016/j.mycmed.2016.12.00228041812
   PubMed Web of Science ®Google Scholar
• Lopez-RibotJL. Candida albicans biofilms: more than filamentation. Curr Biol. 2005;15(12):R453–5. doi:10.1016/j.cub.2005.06.02015964263
   PubMed Web of Science ®Google Scholar
• YaparN. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag. 2014;10:95–105. doi:10.2147/TCRM.S4016024611015
   PubMed Web of Science ®Google Scholar
• AndersonMZ, SahaA, HaseebA, et al. A chromosome 4 trisomy contributes to increased fluconazole resistance in a clinical isolate of Candida albicans. Microbiology. 2017;163(6):856–865. doi:10.1099/mic.0.00047828640746
   PubMed Web of Science ®Google Scholar
• LiY, JiaoP, LiY, et al. The synergistic antifungal effect and potential mechanism of D-penicillamine combined with fluconazole against Candida albicans. Front Microbiol. 2019;10. doi:10.3389/fmicb.2019.02853
   Web of Science ®Google Scholar
• GongY, LiuW, HuangX, et al. Antifungal activity and potential mechanism of N-butylphthalide alone and in combination with fluconazole against Candida albicans. Front Microbiol. 2019;10:1461. doi:10.3389/fmicb.2019.0146131312187
   PubMed Web of Science ®Google Scholar
• YoosefianM, RahmanifarE, EtminanN. Nanocarrier for levodopa Parkinson therapeutic drug; comprehensive benserazide analysis. Artif Cells Nanomed Biotechnol. 2018;46(sup1):434–446. doi:10.1080/21691401.2018.143058329378432
   PubMed Web of Science ®Google Scholar
• LiW, ZhengM, WuS, et al. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. J Exp Clin Cancer Res. 2017;36(1):58. doi:10.1186/s13046-017-0530-428427443
   PubMed Web of Science ®Google Scholar
• LaurianR, DementhonK, DoumècheB, et al. Hexokinase and glucokinases are essential for fitness and virulence in the pathogenic yeast Candida albicans. Front Microbiol. 2019;10:327. doi:10.3389/fmicb.2019.0032730858840
   PubMed Web of Science ®Google Scholar
• ChenX, ZhangZ, ChenZ, et al. Potential antifungal targets based on glucose metabolism pathways of Candida albicans. Front Microbiol. 2020;11:296. doi:10.3389/fmicb.2020.0029632256459
   PubMed Web of Science ®Google Scholar
• KruszewskaH, ZarebaT, TyskiS. Examination of antimicrobial activity of selected non-antibiotic drugs. Acta Pol Pharm. 2004;61(Suppl):18–21.15909927
   PubMedGoogle Scholar
• LockhartSR, BoldenCB, IqbalN, et al. Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference method. J Clin Microbiol. 2011;49(12):4322–4325. doi:10.1128/JCM.05479-1122012016
   PubMed Web of Science ®Google Scholar
• LiuX, LiT, WangD, et al. Synergistic antifungal effect of fluconazole combined with licofelone against resistant Candida albicans. Front Microbiol. 2017;8:2101. doi:10.3389/fmicb.2017.0210129163396
   PubMed Web of Science ®Google Scholar
• LuM, YanH, YuC, et al. Proton pump inhibitors act synergistically with fluconazole against resistant Candida albicans. Sci Rep. 2020;10(1):498. doi:10.1038/s41598-019-57174-431949170
   PubMed Web of Science ®Google Scholar
• LiX, ZhaoY, HuangX, et al. Ambroxol hydrochloride combined with fluconazole reverses the resistance of Candida albicans to fluconazole. Front Cell Infect Microbiol. 2017;7:124. doi:10.3389/fcimb.2017.0012428439502
   PubMed Web of Science ®Google Scholar
• OddsFC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1. doi:10.1093/jac/dkg30112805255
   PubMed Web of Science ®Google Scholar
• RamageG, Lopez-RibotJL. Techniques for antifungal susceptibility testing of Candida albicans biofilms. Methods Mol Med. 2005;118:71–79. doi:10.1385/1-59259-943-5:07115888936
   PubMedGoogle Scholar
• RamageG, Vande WalleK, WickesBL, et al. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother. 2001;45(9):2475–2479. doi:10.1128/AAC.45.9.2475-2479.200111502517
   PubMed Web of Science ®Google Scholar
• GagoS, García-RodasR, CuestaI, et al. Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis virulence in the non-conventional host Galleria mellonella. Virulence. 2014;5(2):278–285. doi:10.4161/viru.2697324193303
   PubMed Web of Science ®Google Scholar
• KrezdornJ, AdamsS, CootePJ. A Galleria mellonella infection model reveals double and triple antibiotic combination therapies with enhanced efficacy versus a multidrug-resistant strain of Pseudomonas aeruginosa. J Med Microbiol. 2014;63(Pt 7):945–955. doi:10.1099/jmm.0.074245-024928215
   PubMed Web of Science ®Google Scholar
• LiY, YangJ, LiX, et al. The effect of Ginkgolide B combined with fluconazole against drug-resistant Candida albicans based on common resistance mechanisms. Int J Antimicrob Agents. 2020;56(2):106030.32454072
   PubMed Web of Science ®Google Scholar
• ShiW, ChenZ, ChenX, et al. The combination of minocycline and fluconazole causes synergistic growth inhibition against Candida albicans: an in vitro interaction of antifungal and antibacterial agents. FEMS Yeast Res. 2010;10(7):885–893. doi:10.1111/j.1567-1364.2010.00664.x20707818
   PubMed Web of Science ®Google Scholar
• GrynkiewiczG, PoenieM, TsienRY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260(6):3440–3450. doi:10.1016/S0021-9258(19)83641-43838314
   PubMed Web of Science ®Google Scholar
• ChenX, ShiY, LiY, et al. Antifungal effects and potential mechanisms of lonidamine in combination with fluconazole against Candida albicans. Expert Rev Anti Infect Ther. 2021;19(1):109–115. doi:10.1080/14787210.2020.181168432924656
   PubMed Web of Science ®Google Scholar
• LuM, YuC, CuiX, et al. Gentamicin synergises with azoles against drug-resistant Candida albicans. Int J Antimicrob Agents. 2018;51(1):107–114. doi:10.1016/j.ijantimicag.2017.09.01228943366
   PubMed Web of Science ®Google Scholar
• MalmquistJA, RoganMR, McGillivraySM. Galleria mellonella as an infection model for Bacillus anthracis Sterne. Front Cell Infect Microbiol. 2019;9:360. doi:10.3389/fcimb.2019.0036031681636
   PubMed Web of Science ®Google Scholar
• GibreelTM, UptonM. Synthetic epidermicin NI01 can protect Galleria mellonella larvae from infection with Staphylococcus aureus. J Antimicrob Chemother. 2013;68(10):2269–2273.23711896
   PubMed Web of Science ®Google Scholar
• BhattacharyaS, SobelJD, WhiteTC. A combination fluorescence assay demonstrates increased efflux pump activity as a resistance mechanism in azole-resistant vaginal candida albicans isolates. Antimicrob Agents Chemother. 2016;60(10):5858–5866.27431223
   PubMed Web of Science ®Google Scholar
• MonteiroKL, de AquinoTM, Mendonça JuniorFJB. An update on Staphylococcus aureus NorA efflux pump inhibitors. Curr Top Med Chem. 2020;20(24):2168–2185. doi:10.2174/156802662066620070413583732621719
   PubMed Web of Science ®Google Scholar
• DonaduMG, Peralta-RuizY, UsaiD, et al. Colombian essential oil of ruta graveolens against nosocomial antifungal resistant candida strains. J Fungi. 2021;7(5):383. doi:10.3390/jof7050383
   Web of Science ®Google Scholar
• DonaduM, UsaiD, MarchettiM, et al. Antifungal activity of oils macerates of North Sardinia plants against Candida species isolated from clinical patients with candidiasis. Nat Prod Res. 2020;34(22):3280–3284. doi:10.1080/14786419.2018.155717530676066
   PubMed Web of Science ®Google Scholar
• PinnaA, DonaduMG, UsaiD, et al. In vitro antimicrobial activity of a new ophthalmic solution containing hexamidine diisethionate 0.05%(keratosept). Cornea. 2020;39(11):1415–1418. doi:10.1097/ICO.000000000000237532452982
   PubMed Web of Science ®Google Scholar
• PinnaA, DonaduMG, UsaiD, et al. In vitro antimicrobial activity of a new ophthalmic solution containing povidone-iodine 0.6% (IODIM®). Acta Ophthalmol. 2020;98(2):e178–e180. doi:10.1111/aos.1424331486592
   PubMed Web of Science ®Google Scholar
• LiX, YuC, HuangX, et al. Synergistic effects and mechanisms of budesonide in combination with fluconazole against resistant Candida albicans. PLoS One. 2016;11(12):e0168936. doi:10.1371/journal.pone.016893628006028
   PubMed Web of Science ®Google Scholar
• ZhangM, YanH, LuM, et al. Antifungal activity of ribavirin used alone or in combination with fluconazole against Candida albicans is mediated by reduced virulence. Int J Antimicrob Agents. 2020;55(1):105804. doi:10.1016/j.ijantimicag.2019.09.00831605727
   PubMed Web of Science ®Google Scholar
• KojicEM, DarouicheRO. Candida infections of medical devices. Clin Microbiol Rev. 2004;17(2):255–267. doi:10.1128/CMR.17.2.255-267.200415084500
   PubMed Web of Science ®Google Scholar
• BrennanM, ThomasDY, WhitewayM, et al. Correlation between virulence of Candida albicans mutants in mice and Galleria mellonella larvae. FEMS Immunol Med Microbiol. 2002;34(2):153–157. doi:10.1111/j.1574-695X.2002.tb00617.x12381467
   PubMedGoogle Scholar
• FrenkelM, MandelblatM, Alastruey-IzquierdoA, et al. Pathogenicity of Candida albicans isolates from bloodstream and mucosal candidiasis assessed in mice and Galleria mellonella. J Mycol Med. 2016;26(1):1–8. doi:10.1016/j.mycmed.2015.12.00626852192
   PubMed Web of Science ®Google Scholar
• MylonakisE, MorenoR, El KhouryJB, et al. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun. 2005;73(7):3842–3850. doi:10.1128/IAI.73.7.3842-3850.200515972469
   PubMed Web of Science ®Google Scholar
• LiY, SunL, LuC, et al. Promising antifungal targets against Candida albicans based on ion homeostasis. Front Cell Infect Microbiol. 2018;8:286. doi:10.3389/fcimb.2018.0028630234023
   PubMed Web of Science ®Google Scholar
• TongY, LiuM, ZhangY, et al. Beauvericin counteracted multi-drug resistant Candida albicans by blocking ABC transporters. Synth Syst Biotechnol. 2016;1(3):158–168. doi:10.1016/j.synbio.2016.10.00129062940
   PubMed Web of Science ®Google Scholar
• YuQ, DingX, ZhangB, et al. Inhibitory effect of verapamil on Candida albicans hyphal development, adhesion and gastrointestinal colonization. FEMS Yeast Res. 2014;14(4):633–641. doi:10.1111/1567-1364.1215024650198
   PubMed Web of Science ®Google Scholar
• YunDG, LeeDG. Silibinin triggers yeast apoptosis related to mitochondrial Ca(2+) influx in Candida albicans. Int J Biochem Cell Biol. 2016;80:1–9. doi:10.1016/j.biocel.2016.09.00827639679
   PubMed Web of Science ®Google Scholar
• ShiraziF, KontoyiannisDP. Micafungin triggers caspase-dependent apoptosis in Candida albicans and Candida parapsilosis biofilms, including caspofungin non-susceptible isolates. Virulence. 2015;6(4):385–394. doi:10.1080/21505594.2015.102747926065323
   PubMed Web of Science ®Google Scholar
• ShirtliffME, KromBP, MeijeringRAM, et al. Farnesol-Induced Apoptosis in Candida albicans. Antimicrob Agents Chemother. 2009;53(6):2392–2401. doi:10.1128/AAC.01551-0819364863
   PubMed Web of Science ®Google Scholar
• HengartnerMO. Apoptosis - DNA destroyers. Nature. 2001;412(6842):27–29. doi:10.1038/3508366311452284
   PubMed Web of Science ®Google Scholar
• YunJ, LeeDG. Cecropin A‐induced apoptosis is regulated by ion balance and glutathione antioxidant system in Candida albicans. IUBMB Life. 2016;68(8):652–662. doi:10.1002/iub.152727338801
   PubMed Web of Science ®Google Scholar
• HaoB, ChengS, ClancyCJ, et al. Caspofungin kills candida albicans by causing both cellular apoptosis and necrosis. Antimicrob Agents Chemother. 2013;57(1):326–332. doi:10.1128/AAC.01366-1223114781
   PubMed Web of Science ®Google Scholar
• PhillipsAJ, SudberyI, RamsdaleM. Apoptosis induced by environmental stresses and amphotericin B in Candida albicans. Proc Natl Acad Sci U S A. 2003;100(24):14327–14332. doi:10.1073/pnas.233232610014623979
   PubMed Web of Science ®Google Scholar
• MishraNN, PrasadT, SharmaN, et al. Pathogenicity and drug resistance in Candida albicans and other yeast species. A review. Acta Microbiol Immunol Hung. 2007;54(3):201–235. doi:10.1556/amicr.54.2007.3.117896473
   PubMedGoogle Scholar
• Viet-KhoaT-N, PrasadR, FalsonP, et al. Modulators of the efflux pump Cdr1p of Candida albicans: mechanisms of action and chemical features. Curr Med Chem. 2017;24(30):3242–3253. doi:10.2174/092986732466617052310224428545374
   PubMed Web of Science ®Google Scholar
• UsaiD, DonaduM, BuaA, et al. Enhancement of antimicrobial activity of pump inhibitors associating drugs. J Infect Devel Countries. 2019;13(02):162–164. doi:10.3855/jidc.11102
   Google Scholar